The 2019 ISV Annual General Meeting took place on October 28 as part of the 2019 ISV Annual Congress in Ghent, Belgium. ISV members in attendance cast their votes for the 2020-2021 ISV Board; members not in attendance were able to vote via email through November 11.

We were pleased to have a number of dedicated ISV members who volunteered to serve as candidates to be potential Board members. As in the past, nominations were solicited two months ahead of the Annual General Meeting through the ISV newsletter and emails to the ISV mailing list, and the official ballots were sent out two weeks ahead of the meeting.

We would like to thank ISV members for their very active participation in this year’s election and the candidates for the board and officer positions. If you would like to be active in ISV, we have many opportunities, outside a Board position, to participate in ISV, so please do not hesitate to contact us and become involved in outreach and supporting vaccine activities.

We wish to thank the dedication and significant achievement by members of the current Board (2018-2019). The current Board members and officers will serve until December 31, 2019.

We welcome the newly elected board members and officers; we are looking forward to working together to continue to promote our Society!

David Weiner, President (2018-2019)
Ted Ross, President-Elect (2020-2021)

ISV Officers (2020–2021)
President, Ted Ross, USA (formerly President-elect)
President Emeritus, David Weiner, USA (formerly President)
President-elect, Denise Doolan, AUS
Treasurer, Shan Lu, USA
Secretary, Linda Klavinskis, UK

ISV Board (2020–2021)
Randy A. Albrecht, USA
Lars Frelin, Sweden
Manon Cox, Netherlands
Gary Kobinger, Canada
Punnee Pitisuttithum, Thailand
Margaret Liu, USA
Joon Haeng Rhee, South Korea
Leonard Moise, USA
Jeffrey Ulmer, USA
Xavier Saelens, Belgium

Please join us in....
Québec City, Canada
October 10th—October 13th, 2020
Québec City Convention Centre
Measles virus infection diminishes preexisting antibodies that offer protection from other pathogens.


Journal article abstract: "Measles virus is directly responsible for more than 100,000 deaths yearly. Epidemiological studies have associated measles with increased morbidity and mortality for years after infection, but the reasons why are poorly understood. Measles virus infects immune cells, causing acute immune suppression. To identify and quantify long-term effects of measles on the immune system, we used VirScan, an assay that tracks antibodies to thousands of pathogen epitopes in blood. We studied 77 unvaccinated children before and 2 months after natural measles virus infection. Measles caused elimination of 11 to 73% of the antibody repertoire across individuals. Recovery of antibodies was detected after natural reexposure to pathogens. Notably, these immune system effects were not observed in infants vaccinated against MMR (measles, mumps, and rubella), but were confirmed in measles-infected macaques. The reduction in humoral immune memory after measles infection generates potential vulnerability to future infections, underscoring the need for widespread vaccination."

Immunogenicity of chimeric haemagglutinin-based, universal influenza virus vaccine candidates: interim results of a randomised, placebo-controlled, phase 1 clinical trial.


Current influenza vaccines protect against influenza only when well matched to the circulating strains. Therefore, there is an unmet medical need for a broadly protective influenza virus vaccine. Bernstein and colleagues tested the ability of chimeric H1 haemagglutinin-based universal influenza virus vaccine candidates to induce broadly cross-reactive antibodies targeting the stalk domain of group 1 haemagglutinin-expressing influenza viruses. The authors reported that the tested chimeric haemagglutinin-based, universal influenza virus vaccine regimens elicited cross-reactive serum IgG antibodies that targeted the conserved haemagglutinin stalk domain.

Visit the ISV website to view previous Papers of the Month.

2019 ISV Congress Award Recipients

- ISV Richard Ginsberg award*, Lin Ching Ong, University of Gothenburg, Sweden
- ISV Richard Ginsberg award*, 1st runner up, Joshua Gillard, Radboud University Medical Center, Netherlands
- ISV Maurice Hilleman award, Nadine Salisch, Janssen Vaccines, Leiden, Netherlands
- ISV Bright Sparks in Vaccinology award, Makutio Masavuli, University of Adelaide, Australia
- ISV Bright Sparks in Vaccinology 1st runner up, Hannah Sharpe, Jenner Institute, University of Oxford, UK
- ISV Best Poster award, Rachel Sattler, University of Texas Medical Branch at Galveston, USA
- ISV Best poster award 1st runner up, National Institutes of Biomedical Innovation, Health and Nutrition, Japan
- ISV best poster 2nd runner up, Ronan Rouxel, GSK Vaccines, Belgium

ISV trainee awards: Angela Choi (USA), Danika Hill (UK), Julia Marshall (UK), Marion “Ian” Setliff (USA), and Jelle van Schooten (The Netherlands)

LMIC awardees: Omolara Baiyegunhi (South Africa), Dominicus Husada (Indonesia), Muhammet Karakavuk (Turkey), Fei Kean Loh (Malaysia), Sindiswa Lukhele (South Africa), Farzin Roohvand (Iran)

International Veterinary Vaccinology Network (IVV-N) trainee award recipients: Jose Manuel Jaramillo Ortiz (Argentina ), Nembangwa Derrick Neba (Cameroon), Emmaculate Yaah Ntang (Cameroon)

*In recognition of Dr. Richard S. Ginsberg, who was a major proponent of the DNA vaccine field and innovator of new treatments and vaccine technologies for the developing world.
Dr. Randy A. Albrecht, November 2019 ISV Fellow of the Month

Dr. Albrecht earned his Doctor of Philosophy degree in Microbiology and Immunology from the Louisiana State University Health Sciences Center, Shreveport, Louisiana in 2003 under the mentorship of Dr. Dennis J. O’Callaghan. He conducted his postdoctoral studies in the laboratory of Dr. García-Sastre in the Department of Microbiology at the Icahn School of Medicine at Mount Sinai, New York. Specific areas of research have focused on developing novel influenza vaccines, studying humoral responses of animals and humans to influenza vaccines, developing immunological reagents and assays to examine the adaptive immune response of ferrets, testing the protective efficacy of novel influenza vaccines in small animal models of influenza disease, and in vitro assays of antibody-mediated virus neutralization. Novel influenza vaccines that induce protective immunity against more conserved antigens such as the hemagglutinin stalk domain are an exciting and rapidly developing area of research on influenza virus vaccines. These vaccine approaches hold the promise to induce broadly neutralizing antibody and cellular immune responses that could confer increased protection against antigenic drift and possibly against pandemic influenza. Dr. Albrecht has contributed to preclinical research studies that have examined in the ferret model of influenza the potential of sequential immunization regimens with vaccines that are designed to focus humoral immune responses against the conserved hemagglutinin stalk domain. Dr. Albrecht, an active member of ISV, serves as the Editor of the ISV newsletter. Dr. Albrecht served on the Scientific Organizing Committee for the 2018 Annual ISV Congress held in Atlanta, Georgia (USA), and was elected a member of the ISV Executive Board (2020-2021).

Dr. Rafi Ahmed, December 2019 ISV Fellow of the Month

Dr. Rafi Ahmed is a world-renowned immunologist who holds positions of Professor in the Department of Microbiology and Immunology at Emory University, Director of the Emory Vaccine Center, Eminent Scholar of the Georgia Research Alliance, and Investigator at the Emory Center for AIDS Research. In 1981, he received his Ph.D. in Microbiology from Harvard University after studying for four years in the laboratory of Dr. Bernard Field. Dr. Ahmed then completed a three-year postdoctoral fellowship that he focused on cytotoxic T lymphocytes while in the laboratory of Michael B. Oldstone at the Scripps Institute in La Jolla, California. Dr. Ahmed’s accolades include Member of the U.S. National Academy of Sciences (2009), Foreign Member of the Indian National Academy of Sciences (2013), Member of the Institute of Medicine (2014), Member of the National Academy of Sciences (2014), AAI Excellence in Mentoring Award (2015), Robert Koch Award (2017), and William B. Coley Award for Distinguished Research in Basic Immunology (2017). Dr. Ahmed’s early seminal discovery that T cell exhaustion during chronic viral infections is linked to the PD-1 inhibitory receptor opened a new area of research on PD-1-directed immunotherapeutic approaches for chronic infections and cancer. Dr. Ahmed served as the local co-chair for the 2018 Annual ISV Congress held in Atlanta, Georgia (USA), and served on the Scientific Organizing Committee for the 2019 Annual ISV Congress held in Ghent, Belgium.
Nadine Salisch received the **Maurice Hilleman Award** for the most outstanding abstract.

Dr. Adrian B McDermott presents during the **Next Generation Tools and Technologies for Vaccine Development** session.

ISV Congress Career Panelists (Left to Right) Staelens, Mahase, Dyrberg, Catanese, Degun, and Carrat.

ISV Congress Career Panel participants receive advice on career pathways and networking opportunities.

Attendees enjoy hors d’oeuvres during the gala dinner at Thagaste within the Monastery of the Augustinian Fathers.

Lin Ching Ong received the **Richard Ginsburg Award** for the best oral presentation by a trainee.
Hwasun International Vaccine Forum

The 2019 Hwasun International Vaccine Forum (HIVF) was successfully held at the Hwasun Hanium Culture Sport Center from November 7 to 8, 2019. The vaccine industry is undergoing many technological innovations. Newly emerging infectious diseases urge a paradigm change in the way we develop new vaccines. The Hwasun International Vaccine Forum aimed to envision the future of the vaccine industry. The Forum coincided with the Vaccine Immunotherapy International Symposium at the Hwasun Hanium Culture Sports Center in Hwasun, Jeollanam-do, Republic of Korea; the only special vaccine industrial district endorsed by the Korean Government.

The Forum brought together experts from vaccine research institutions, companies, governments, and international organizations from around the world. The Forum, with the theme, “The Future of Therapeutic Vaccine and Immunotherapy,” included presentations by distinguished authorities from the vaccine field. The Forum focused on current challenges in vaccine research and development, innovative vaccines in the product development pipeline, the international ethics of developing vaccines against emerging infectious diseases, and national vaccine policies that pertained to the Republic of Korea. The HIVF included 1,100 registrants including, researchers, students, government officials, industrial practitioners, and world renowned experts in vaccine and immunotherapy, such as David Weiner (ISV President, Executive Vice-President of the Wistar Institute), Sin-Hyeog Im (Professor, POSTECH), and Frank Fan (CSO and founder, Nanjing Legend Biotechnology).

Preparations for the 2020 HIVF are underway. For additional details, contact Joon Haeng Rhee or Eva Yim.

ISV President, Dr. David Weiner of the Wistar Institute, presents at the 2019 Hwasun International Vaccine Forum.

International Society for Vaccines

ISV has a social medial presence with 177 Facebook members and over 5815 LinkedIn members. Join us online to take part in discussions or to find out what is happening in the society. We would like your ideas for future newsletter articles. Is there an article you’d like to submit to the newsletter? What are the most pressing issues in vaccine research? Please send us your thoughts.

Contact us:
Society website: http://isv-online.org/
LinkedIn: https://www.linkedin.com/groups/8359482/profile
Instagram: @intl_society_for_vaccines https://www.instagram.com/intl_society_for_vaccines/
2019 ISV Congress: http://isvcongress.org/
**Contact information**

**CONSORTIUM COORDINATOR**
**PARTNERSHIP MANAGEMENT**
Prof. Christine DELPRAT
Université Claude Bernard Lyon 1
Lyon – France
christine.delprat@univ-lyon1.fr

**SELECTION / ADMISSION MANAGER**
**Dolores JARAQUEMADA PÉREZ DE GUZMÁN**
Universitat Autònoma de Barcelona
Barcelona – Spain
Dolores.Jaraquemada@uab.cat

**Prof. Thomas STRATMANN**
Universitat de Barcelona
Barcelona – Spain
thomas.stratmann@ub.edu

**QUALITY ASSURANCE MANAGER**
**Prof. Peter DELPUTTE**
University of Antwerp
Antwerp – Belgium
peter.delputte@uantwerpen.be

**COMMUNICATION MANAGER**
**Dr. Stéphane PAUL**
Université Jean Monnet Saint-Etienne
Saint-Etienne – France
stephane.paul@chu-st-etienne.fr

Dead line for student application: 2020, 23rd January

Update 2019-11-05
Erasmus+ LIVE IMD Programme is a unique European Master in Vaccinology dedicated to:

- Train the students from all countries to different cultures.
- Organize an integrated formation with a strong scientific background in Immunology, Infectiology, Vaccinology, but also multilingualism and multidisciplinarity; legislation, health policy and humanities around vaccinology.
- Integrate know-how, know-what, know-why & know-who along the vaccinology chain: fundamental and translational research, industrial development and production, usage and epidemiological follow-up in vaccine clinical centres and communication.
- Drive a very efficient and opened joint training between the academic and the industrial world to cover a defined list of jobs in agreement with the labour market.
- Annually organize the VaxInLive SYMPOSIAS international meetings

The Worldwide Partnership is already rich of:

- 12 Academic Universities in Brazil, China, Cuba, Europe and USA (see § Partner Universities)
- 16 Clinical and Research Centres in Brazil, Burkina Faso, Cameroon, Europe, Mali, Senegal and South Korea
- 12 Health and Research Organizations: WHO, Vaccines Europe, Fondation Mérieux, REIVAC, CofReVac, BIOASTER, Lyon BIPOLY, Vaccine Formulation Institute, NEST, EVI, HSET, and ISGlobal
- 17 Industrial partners and vaccine manufacturers: BioMérieux, Institut Mérieux, Janssen Vaccines, GSK Vaccines, Merial, Pfizer, ABL Lyon, Sanofi Pasteur, Transgene, Valneva, Virbac, Takeda, Amal Therapeutics, Vakzine Projekt Management, Immuno Valley, Incepta Vaccine, Intravacc
- 2 experienced European and Swiss digital learning platforms: Claroline Connect and HSeT Foundation

Mobility: The LIVE Master Programme benefit from industrial training support and is organized at leading European Universities, in charge of awarding 120 credits (30 ECTS / semester) for 2 years in at least 3 places. Students move from Barcelona in Spain (Semester 1), via Antwerp in Belgium (S2) then Lyon in France (S3), to the Partner of the world (S4) they choose for their Master thesis (Worldwide Partnership).

Courses include teaching of general skills such as scientific writing and presentation, time management, vaccine and society, careers, digital skills and intercultural communication with improvement in two foreign languages and participation to the Summer School on Vaccinology.

- S1-S2: Fundamental scientific and multidisciplinary aspects of Immunology, Immunopathology, Cancer Immunology, Infectiology, Epidemiology, Research and Clinical Vaccinology, Public Health, Advertising, bioinformatics data scientist, Project Management and Confidence in Vaccination. S1-S3 also include:
  - Focus on specialized topics such as vaccine formulation and safety, aged and newborn immune systems, host-pathogen interactions, cancer, vaccine manufacturing and quality control process, animal course and clinical vaccine trials.
  - Methods and techniques of modern vaccinology including statistics, “omics”, computer modelling approaches.
- S4: students have the opportunity to apply their knowledge worldwide with an internship supervised by our associated partners and to write and defend a Master thesis, a major achievement for graduation.

Student Looking for Mobility and Courses in ENGLISH? Join us!

Vaccines are an Important Cornerstone of the Public Health System.

More than 60% of the world’s vaccine production sites are based in Europe, employing over 20,000 people. The world faces constant infectious health threats: novel or mutated viruses, epidemiological outbreaks, or the unmet challenges to fight some of the most dangerous known pathogens. Future vaccinology applications will target immunopathologies and cancers. It is thus timely to educate the next generation of vaccinologists, trained in a multidisciplinary and integrated way in order to speed up the process from vaccine discovery to its positive impact on world human health.

Roles and Benefits for Associate Partner

They actively participate according to their skills and ability to fund the training of their future highly competent colleagues. They can:

- Interact with the LIVE network composed of #50 institutions, big Pharma and Biotech that have so far joined our LIVE Master initiative to support this project
- Take part in the teaching for specific topics or MOOC building
- Fund total or part of scholarship: 50k€/student /2 years
- As funders, become member of the Academic and Management Board, the decision-making body of LIVE
- Organize their site visit, possibly with formation on site
- Assist in the dissemination, promotion and evaluation of LIVE
- Provide internship (up to 6 months) subject and professional tutorship to gain highly qualified trainees at LIVE semester 4
- Offer a job or PhD position to the selected graduated Master student they trust as their future excellently trained colleague participate in the VaxInLive SYMPOSIAS international meetings.

Future Associate Partner? Join us!

The vast majority of the world’s vaccines are produced in Europe.

Europe exports more than 80% of its production, 3.4 billion doses per year.